Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Anorexia 5Neoplasms 4Weight Loss 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Cachexia 2Breast Neoplasms 2Sleep Initiation and Maintenance Disorders 1Neoplasm Metastasis 1Malnutrition 1Lung Neoplasms 1Head and Neck Neoplasms 1Depressive Disorder, Major 1Depression 1Body Weight 1Anorexia Nervosa with Significantly Low Body Weight 1Advanced Cancer 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Mirtazapine × Clear all
NCT04763135 2023-06-08

MIR-P

Hospices Civils de Lyon

Phase 3 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡